Rational approach to diagnostics and treatment of chronic viral hepatitis C


Cite item

Full Text

Abstract

Virus of hepatitis C is the only virus of Hepadnovirus line in the Flaviviridae family which includes RNA. It was found in 199o as a etiologic agent of posttransfusion non-A, non-B hepatitis. Chronic hepatitis C is the main etiologic factor of chronic hepatitis, cirrhosis and hepatocellular carcinoma. In 1999 in Russia the morbidity of hepatitis C was 19,3 on 100 thousand of population. The course of hepatitis is often asymptomatic. In 20-30% of patients with chronic infection it transforms in cirrhosis during the 20 years. The article includes the epidemiology and pathogenesis of chronic hepatitis C and modem algorithms of its diagnostics and treatment.

References

  1. Fried MW, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
  2. Edlin BR. Five million Americans infected with the hepatitis C virus: a corrected estimate. Hepatology 2005;42(Suppl. 1):213A.
  3. Рациональная фармакотерапия заболеваний органов пищеварения. Руководство для практических врачей / Под ред. В.Т. Ивашкина. М, 2003. 1046 с.
  4. Kenny-Walsh K, et al. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-33.
  5. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
  6. Seeff LB, et al. Long-term mortality after transfusionassociated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992;327:1906-11.
  7. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-73.
  8. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-801.
  9. Hepatitis Surveillance Report N 56 Atlanta: Centers for Disease Control and Prevention; 1996:1-36.
  10. Knodell RG, Ishak KG, Black WC, et. al. Formulation and application of numeral scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepotology 1981;1:431-35.
  11. Seeff LB, et al. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002;36(5 Suppl. 1):S1-2.
  12. Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001;34:223-29.
  13. Zeuzem S. Standart therapie der akuten und chronischen Hepatitis C. Z Gastroenterol 2004;42:714-19.
  14. Чуланов В.П. Молекулярные методы диагностики и оптимизация лечения хронического гепатита С // Клиническая гепатология. 2007. № 2. С. 19-25.
  15. Isaka Y, Nishi Y, Ito Y, et al. Ophthalmic manifestations of interferon therapy in eight patients. Folia Ophthalmol Jpn 1993;44:1054-58.
  16. Manns MP, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies